Bayer AG's head of pharma Dieter Weinand has warned the pharma industry it should act now to help broaden thinking and remove silos related to value-based assessments for new drugs, if it wants to unlock the next scientific revolution arising from breakthroughs like CRISPR gene editing.
"We are on the cusp of the next scientific revolution and we need to figure out how, comprehensively and long-term,...